Protara Therapeutics Statistics
Total Valuation
TARA has a market cap or net worth of $273.67 million. The enterprise value is $76.97 million.
Important Dates
The next estimated earnings date is Friday, May 1, 2026, before market open.
| Earnings Date | May 1, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TARA has 54.08 million shares outstanding. The number of shares has increased by 108.02% in one year.
| Current Share Class | 54.08M |
| Shares Outstanding | 54.08M |
| Shares Change (YoY) | +108.02% |
| Shares Change (QoQ) | +8.92% |
| Owned by Insiders (%) | 1.95% |
| Owned by Institutions (%) | 68.79% |
| Float | 47.43M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.36 |
| P/TBV Ratio | 1.38 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.58, with a Debt / Equity ratio of 0.02.
| Current Ratio | 14.58 |
| Quick Ratio | 14.34 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -31.60% and return on invested capital (ROIC) is -21.73%.
| Return on Equity (ROE) | -31.60% |
| Return on Assets (ROA) | -20.64% |
| Return on Invested Capital (ROIC) | -21.73% |
| Return on Capital Employed (ROCE) | -32.51% |
| Weighted Average Cost of Capital (WACC) | 12.33% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.25M |
| Employee Count | 46 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +17.13% in the last 52 weeks. The beta is 1.50, so TARA's price volatility has been higher than the market average.
| Beta (5Y) | 1.50 |
| 52-Week Price Change | +17.13% |
| 50-Day Moving Average | 5.53 |
| 200-Day Moving Average | 4.99 |
| Relative Strength Index (RSI) | 44.40 |
| Average Volume (20 Days) | 570,719 |
Short Selling Information
The latest short interest is 5.75 million, so 10.62% of the outstanding shares have been sold short.
| Short Interest | 5.75M |
| Short Previous Month | 5.55M |
| Short % of Shares Out | 10.62% |
| Short % of Float | 12.11% |
| Short Ratio (days to cover) | 7.84 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -64.55M |
| Pretax Income | -57.44M |
| Net Income | -57.44M |
| EBITDA | -64.19M |
| EBIT | -64.55M |
| Earnings Per Share (EPS) | -$1.34 |
Full Income StatementBalance Sheet
The company has $155.55 million in cash and $3.36 million in debt, giving a net cash position of $194.53 million or $3.60 per share.
| Cash & Cash Equivalents | 155.55M |
| Total Debt | 3.36M |
| Net Cash | 194.53M |
| Net Cash Per Share | $3.60 |
| Equity (Book Value) | 196.41M |
| Book Value Per Share | 3.67 |
| Working Capital | 148.57M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$56.37 million and capital expenditures -$94,000, giving a free cash flow of -$56.46 million.
| Operating Cash Flow | -56.37M |
| Capital Expenditures | -94,000 |
| Depreciation & Amortization | 362,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -56.46M |
| FCF Per Share | -$1.04 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |